Pfizer, Freeport-McMoRan, Vertex Pharmaceuticals And A Major Tech Stock On CNBC's 'Final Trades'

On CNBC's “Halftime Report Final Trades,” Joshua Brown of Ritholtz Wealth Management said under $30, Pfizer Inc. (NYSE:PFE) is a gift.

Pfizer is looking to build on the success of its COVID-19 vaccine rollout by introducing a direct-to-consumer medicines platform under the brand "Pfizer for All."

Jim Lebenthal of Cerity Partners said QUALCOMM Incorporated (NASDAQ:QCOM) is breaking out right now.

On May 14, Qualcomm and Aramco reported a collaboration that includes accelerating development of industrial 4G/5G NGN ecosystem.

Don't forget to check out our premarket coverage here

Sarat Sethi of DCLA said Freeport-McMoRan Inc. (NYSE:FCX) is a copper play, and demand for copper is going through the roof.

On April 23, Freeport said first-quarter revenue stood at $6.32 billion, beating the consensus of $5.66 billion. Adjusted EPS was 32 cents, beating the consensus of 27 cents.

Amy Raskin of Chevy Chase Trust named Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) as her final trade.

On May 6, Vertex Pharmaceuticals posted stronger-than-expected results for its first quarter.

Price Action:

• Pfizer shares fell 0.2% to close at $28.38 on Tuesday.
• Qualcomm gained 2.6% to settle at $188.97 during Tuesday's session.
• Freeport-McMoRan shares rose 2.8% to settle at $53.48 on Tuesday.
• Vertex Pharmaceuticals shares slipped 0.3% to close at $428.59 on Tuesday.

Check This Out: Cisco, Prestige Consumer Healthcare And 3 Stocks To Watch Heading Into Wednesday

Image: Shutterstock